#USA #Tampa #Immuno-Oncology #TuHURA Biosciences #VISTA Inhibitor

TuHURA Biosciences Q2 2026 Financial Overview

TuHURA Biosciences, Inc. (NASDAQ:HURA), a leading company in the Phase 3 immuno-oncology space, revealed its financial results for the second quarter ending June 30, 2026. The company is dedicated to developing cutting-edge therapies aimed at overcoming resistance associated with cancer immunotherapy.

Dr. James Bianco, the President and CEO of TuHURA, expressed optimism as the company navigates toward several important milestones this year. He mentioned, "We have made significant progress in advancing all our programs forward and are positioned to continue driving towards several anticipated milestones targeted for the second half of the year." Among these milestones is the expected safe-to-proceed feedback from the FDA and the initiation of a Phase 1b/2 study for the VISTA inhibitor in patients with mutNPM1 r/r acute myeloid leukemia (AML).

Key Corporate Developments

In their recent report, TuHURA highlighted several advancements, including the submission of an Investigational New Drug (IND) application for TBS-2025, a VISTA-inhibiting antibody targeting molecularly defined subsets of AML and other hematologic cancers. The FDA provided a positive response regarding the development pathway for TBS-2025, indicating that a previously planned IND meeting was unnecessary.

Financially, the company announced a $50 million credit facility arranged with its largest shareholder. This funding is expected to extend the company's cash reserves into 2028 and will be utilized for ongoing clinical development as well as operational expenses. The terms include an annual interest rate of 12%, with principal repayment set for five years from now.

Anticipated Milestones by Program

The company has laid out a roadmap of goals for the remainder of 2026:

• - IFx-2.0 (Innate Immune Agonist)

- 2H 2026: Anticipate receiving orphan drug designation in Merkel Cell Carcinoma (MCC)
- 1H 2027: Expect preliminary results from IR study with Keytruda® for deep-seated MCC
- 2H 2027: Completion of enrollment in Phase 3 study of IFx-2.0

• - TBS-2025 (VISTA-inhibiting mAb)

- 2H 2026: Initiate Phase 1b/2 trial of VISTA in mutNPM1 r/r AML
- 2H 2026: Anticipate orphan drug designation in AML
- 1H 2027: Expect preliminary safety and response data for TBS-2025

• - MDSC Inhibitors (Bi-specific ADCs)

- 2H 2026: Presentations at key scientific meetings
- 2H 2026: Start ADC in vivo proof-of-concept studies

Financial Import

As of June 30, 2026, TuHURA reported cash and cash equivalents totaling $1.0 million. The second quarter saw research and development expenses rise to $6.6 million in comparison to $4.9 million in the same period last year, a reflection of the company's heightened clinical development activity. General and administrative expenses rose to $2.1 million, attributed chiefly to non-cash stock compensation and costs associated with being publicly traded.

Net cash outflows from operating activities for the first half of the year were reported at $13 million, up from $10.9 million in the previous year. Conversely, net cash flows from financing activities showcased an increase, with $10.6 million raised this period compared to $8.1 million in 2025.

Company Overview

TuHURA Biosciences operates within the evolving context of immuno-oncology, focusing on developing innovative ways to address resistance to cancer therapies. Their flagship product, IFx-2.0, is designed to work in tandem with existing checkpoint inhibitors to enhance treatment efficacy for advanced cancers. They are also committed to advancing TBS-2025, which targets specific subsets of AML, demonstrating their commitment to precision medicine in oncology. The company invites stakeholders and interested parties to follow their progress by visiting their website or connecting through social media channels.

Conclusion

As TuHURA Biosciences continues to navigate its ambitious development plans and address funding needs, the company is making strides toward delivering innovative solutions in the realm of cancer immunotherapy. With critical milestones approaching, investors and patients alike are watching closely for the impact of these promising advancements.

• ---

This article contains forward-looking statements regarding the company’s future performance and plans, and actual results may vary due to various factors outlined in the company’s financial reports.